For Institutions
About
Top Glove Corporation Bhd. is facing shareholder dissatisfaction due to a 29% decline in share price over the past three years, despite a 75% growth in earnings per share (EPS). The upcoming Annual General Meeting on January 8 will provide shareholders an opportunity to question CEO John Lim's compensation, which has increased to RM1.1 million, aligning with industry averages. Shareholders may be reluctant to approve further increases in CEO pay given the lack of share price growth, indicating potential underlying issues affecting the company.
UltraGreen.ai Limited, a Singapore-based firm, has secured regulatory approvals for its Verdye (indocyanine green for injection) in the Philippines and IC-Flow Imaging System V2 in Malaysia. These approvals mark a significant step in the company's expansion in Southeast Asia, addressing the growing healthcare demand. The approvals will enable UltraGreen to support education and clinical adoption of fluorescence-guided surgery techniques. The company aims to enhance surgical decision-making and patient care through its products and AI-powered data platform, reinforcing its commitment to advancing precision surgery in the region.
UltraGreen.ai Limited has received regulatory approvals for its Verdye indocyanine green injectable in the Philippines and the IC-Flow Imaging System V2 in Malaysia. This marks a significant milestone in the company's efforts to expand fluorescence-guided surgery in Southeast Asia, enhancing surgical education and training while strengthening its market position. UltraGreen.ai specializes in fluorescence-guided surgery and digital health solutions, focusing on high-growth healthcare markets in the region.
Top Glove reported a core profit of MYR 37.4 million in the first quarter of the fiscal year 2026, a quarter-on-quarter increase of 48%. The average selling price of gloves declined by 11% year-on-year, but the operating profit margin increased to 4.6%. Sales in Asia and Latin America grew by 20% and 9%, respectively. Management expects selling prices to rise by 2% to 3% per month in the second quarter and has set a sales growth target of 30% for the fiscal year 2026. Maybank Securities maintains a "Neutral" rating with a target price of MYR 0.64
